{
    "clinical_study": {
        "@rank": "99282", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: Apixaban + Placebo (Saline solution)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg  infusion for 30 min Intravenously"
            }, 
            {
                "arm_group_label": "Treatment B: Apixaban + Cofact (4-Factor PCC)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg  infusion for 30 min Intravenously"
            }, 
            {
                "arm_group_label": "Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)", 
                "arm_group_type": "Experimental", 
                "description": "Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg  infusion for 30 min Intravenously"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of two 4-Factor PCC formulations on\n      Apixaban pharmacodynamics in healthy adult subjects."
        }, 
        "brief_title": "A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Anticoagulation", 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  Body Mass Index (BMI) of 18 to 30 kg/m2\n\n          -  Ages 18 to 45 years, including\n\n          -  Women of childbearing potential (WOCBP) on acceptable contraception and with negative\n             pregnancy test and not breastfeeding\n\n        Exclusion Criteria:\n\n          -  History or evidence of coagulopathy\n\n          -  History or evidence of thrombosis such as deep vein thrombosis or other\n             thromboembolic disease or having a first degree relative under 50 years of age with a\n             history of thromboembolic disease\n\n          -  Any significant acute or chronic medical illness or relevant trauma\n\n          -  Any major surgery within 4 weeks of dosing (prior to dosing) or planned within 2\n             weeks after completion of the study\n\n          -  History of heavy menstrual bleeding that has produced anemia within the past 1 year\n\n          -  Current symptomatic or recent gastrointestinal disease or surgery that could impact\n             the absorption of study drug\n\n          -  History of smoking within 1 month prior to dosing\n\n          -  Recent history (within 6 months of dosing) of pregnancy\n\n          -  Use of hormonal contraceptives\n\n          -  Exposure to any investigational drug or placebo within 4 weeks of study drug\n             administration\n\n          -  Use of any agent, including but not limited to Aspirin, Nonsteroidal\n             anti-inflammatory drugs (NSAIDs), Anticoagulants, Fish oil capsules, Gingko, etc,\n             that are known to increase the potential for bleeding, within 2 weeks prior to dosing\n\n          -  History of any severe drug allergy including allergy to Heparin or history of\n             Heparin-induced thrombocytopenia, hypersensitivity to PCCs or Factor Xa inhibitors,\n             or history of allergy to human blood plasma derived products; history of any adverse\n             drug reaction to Anticoagulants or Antiplatelet agents that resulted in excessive\n             bleeding requiring medical intervention"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074358", 
            "org_study_id": "CV185-156", 
            "secondary_id": "2013-000646-18"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A: Apixaban + Placebo (Saline solution)", 
                    "Treatment B: Apixaban + Cofact (4-Factor PCC)", 
                    "Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)"
                ], 
                "intervention_name": "Apixaban", 
                "intervention_type": "Drug", 
                "other_name": "BMS-562247"
            }, 
            {
                "arm_group_label": "Treatment B: Apixaban + Cofact (4-Factor PCC)", 
                "intervention_name": "Cofact (4-Factor PCC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)", 
                "intervention_name": "Beriplex P/N (4-Factor PCC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment A: Apixaban + Placebo (Saline solution)", 
                "intervention_name": "Placebo (Saline solution)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 26, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ETP is a Thrombin Generation Assay (TGA) Parameter\nPre-PCC baseline is defined as the predose sample collected on Day 4, 3 hours after the Apixaban dose of each period\nDay 1 pre-Apixaban baseline is defined as the predose sample collected on Day 1, prior to first Apixaban dose (0 hour)", 
            "measure": "Pharmacodynamic Measure: Endogenous thrombin potential (ETP) change from pre-prothrombin complex concentrate (PCC) baseline and Day 1 pre-Apixaban baseline", 
            "safety_issue": "No", 
            "time_frame": "Day 1-7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and activated anti-factor Xa activity (AXA)", 
                "measure": "Pharmacodynamic Measures:Change from pre-PCC baseline and Day 1 pre-Apixaban baseline for other TGA parameters (Lag Time, Peak, Time to Peak and Velocity Index), PT, INR, aPTT and AXA", 
                "safety_issue": "No", 
                "time_frame": "Day 1-7"
            }, 
            {
                "description": "The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance", 
                "measure": "Safety assessments based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 41 days"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Maximum observed plasma concentration (Cmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Time of maximum observed plasma concentration (Tmax) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Area under the concentration-time curve in one dosing interval [AUC(0-12)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Area under the plasma concentration-time curve from time zero to 24 hours after dose administration [AUC(0-24)] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Trough observed plasma concentration at the end of one dosing interval (12h) [Cmin] of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }, 
            {
                "measure": "Multiple-dose pharmacokinetic parameter: Terminal elimination half-life (T-HALF) of Apixaban", 
                "safety_issue": "No", 
                "time_frame": "45 timepoints up to day 35"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}